Targeted Nitroxoline Delivery for Treatment of Multidrug-resistant Pathogens (TANDEM)

靶向硝基喹啉递送治疗多重耐药病原体 (TANDEM)

• 批准号: MR/X031632/1
• 负责人: Kerstin Sander
• 金额: $ 32.16万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FX031632%2F1
• 关键词: Targeted; Nitroxoline; Delivery; Treatment; Multidrug

Bacteria and other disease-causing organisms that can no longer be controlled or killed with medicines are called multidrug-resistant organisms (MDROs). MDROs pose a major problem to the healthcare system as they can cause severe infections and affect the weakest, in particular young children, the elderly or people with health conditions such as chronic lung, heart, and kidney disease. In Europe, MDROs cause approximately 670,000 infections per year. 33,000 patients do not survive the infection due to the lack of treatment options.Our aim is to develop a much-needed new strategy for the treatment of MDROs. To this end, we have designed a 'nitroxoline shuttle'. Nitroxoline is an antibiotic drug that effectively kills a broad variety of bacteria; however, its use is limited to bladder infections due to its inability of reaching other parts of the human body. The 'shuttle' is a chemical substance that, when linked to nitroxoline, will allow to safely transport this powerful antibiotic to bacteria in various parts of the human body. In the project, we will manufacture the 'nitroxoline shuttle' and carry out tests to characterise its ability to kill bacteria in a targeted manner.

不能再用药物控制或杀死的细菌和其他致病生物体被称为多药耐药生物体（MDRO）。MDRO对医疗保健系统构成了一个重大问题，因为它们可能导致严重感染并影响最弱的人，特别是幼儿，老年人或患有慢性肺病，心脏病和肾病等健康状况的人。在欧洲，MDRO每年造成约670，000例感染。33，000名患者因缺乏治疗选择而无法存活。我们的目标是制定急需的MDRO治疗新策略。为此，我们设计了一种“硝羟喹啉穿梭机”。硝羟喹啉是一种抗生素药物，可有效杀死多种细菌;然而，由于其无法到达人体的其他部位，其使用仅限于膀胱感染。“穿梭”是一种化学物质，当与硝羟喹啉连接时，将允许安全地将这种强大的抗生素运送到人体各个部位的细菌。在该项目中，我们将制造“硝羟喹啉穿梭机”，并进行测试，以验证其有针对性地杀死细菌的能力。